title: Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
abstract: To evaluate the efficacies and treatment outcomes following intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR), and laser photocoagulation (LPC) in retinopathy of prematurity (ROP).
  
  
  
  This was a retrospective interventional case series study including the data of 134 infants (264 eyes) who were treated with IVB, IVR, or LPC for ROP. The data were collected from two major ROP treatment centers in Turkey without any randomization or masking. Regression of ROP, recurrence profile, complications after each treatment modality, and indications for retreatment were evaluated. The main outcome measures included the total inactivation of ROP with anatomic and refractive outcomes at 1.5 years of adjusted age.
  
  
  
  There were 55 infants (41.1%) in the IVB group, 22 infants (16.4%) in the IVR group, and 57 infants (42.5%) in the LPC group. All but 3 infants (5.5%) in the IVB group and 11 infants (50%) in the IVR group showed recurrence to stage 1 and 2 ROP following IVB and IVR (p < 0.001). Retreatment was performed in three infants in both IVB and IVR groups (p = 0.098). At 1.5 years of adjusted age, all infants showed favorable anatomic outcome except one infant in the LPC group. No significant difference of the mean spherical equivalent (SE) was observed between the groups (p = 0.131). In Zone I ROP, laser treated infants had significantly higher rates of myopia and high myopia than IVB and IVR treated infants (p = 0.040 and p = 0.019, respectively).
  
  
  
  Both IVB and IVR treated infants had significantly better refractive outcomes in Zone I ROP as compared to LPC treated infants at 1.5 years of adjusted age. The higher rate of disease recurrence was associated with IVR. Gestational age (GA) and the zone of ROP were also predictive factors for recurrence of ROP in the study.
authors.affiliation: a Department of Ophthalmology , Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital , Istanbul , Turkey.
authors.forename: Murat
authors.initials: M
authors.lastname: Gunay
authors.affiliation: b Department of Ophthalmology , Adana Numune Training and Research Hospital , Adana , Turkey.
authors.forename: Emine Alyamac
authors.initials: EA
authors.lastname: Sukgen
authors.affiliation: a Department of Ophthalmology , Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital , Istanbul , Turkey.
authors.forename: Gokhan
authors.initials: G
authors.lastname: Celik
authors.affiliation: b Department of Ophthalmology , Adana Numune Training and Research Hospital , Adana , Turkey.
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Kocluk
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000068258:Bevacizumab / Q000008:administration & dosage*; D005260:Female; D005865:Gestational Age; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage*; D012178:Retinopathy of Prematurity / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery; D012189:Retrospective Studies; D016896:Treatment Outcome; D014421:Turkey / Q000453:epidemiology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Bevacizumab; intravitreal injection; laser photocoagulation; ranibizumab; retinopathy of prematurity